Investors / Italy / Panakes Partners
Panakes Partners
Venture capital · Italy · Europe
Panakes Partners is a venture capital firm that backs start-ups and SMEs with innovative products in Life Sciences, providing financial and business support. It manages three funds and reports offices in Milan and Rome, Italy.
Invests inHealthcare & Biotech
In its own wordslife sciencesbiotechmedtechdiagnosticshealthcare
Your fit with Panakes Partners
Four questions about your startup
See how your round matches what it backs, point by point.
Or find every investor that fitsPanakes Partners lists 5 checked portfolio companies on its own site and is named in 5 funding rounds, 1 of them as lead. Its most frequent entry is Growth, 40% of the companies with a known first round. Its largest theme is Healthcare & Biotech (100%). 40% of its companies are based in Switzerland. It invests most often alongside 415 Capital, CDP Venture Capital and Sofinnova Partners.
Counts come from funding rounds that name Panakes Partners, complete from mid-2025: earlier rounds appear only when they were reported later. Round amounts and full round histories are on Fundup AI.
Entry stage
share of companies by the stage of its first roundPanakes Partners does not state its stages on its site, so only what it does is shown.
Show as a table
| Value | |
|---|---|
| Pre-seed | 0% |
| Seed | 20% |
| Series A | 20% |
| Series B | 20% |
| Growth | 40% |
Activity by year
rounds it joined, last 10 yearsShow as a table
| Total | Rounds it led | |
|---|---|---|
| '17 | 0 | 0 |
| '18 | 0 | 0 |
| '19 | 0 | 0 |
| '20 | 0 | 0 |
| '21 | 0 | 0 |
| '22 | 0 | 0 |
| '23 | 0 | 0 |
| '24 | 2 | 1 |
| '25 | 1 | 0 |
| '26 | 2 | 0 |
Investor profile
percentile among all firmsShow as a table
| Measure | Percentile of all firms | Value |
|---|---|---|
| Portfolio size | 4th | 5 companies |
| Recent activity | 69th | 2 rounds in 12 months |
| Early stage | 58th | 20% of entries at pre-seed or seed |
| Evidence | 52th | 0% of companies confirmed by a round |
| Sector focus | 100th | 100% in its largest sector |
| Reach | 70th | 4 countries |
Invests most often with
firms sharing its portfolio companiesShow as a table
| Share | |
|---|---|
| 415 Capital | 2 |
| CDP Venture Capital | 2 |
| Sofinnova Partners | 2 |
| 5AM Ventures | 1 |
| Angelini Ventures | 1 |
| Broadview Ventures | 1 |
| Gilde Healthcare | 1 |
| Indaco Venture Partners SGR | 1 |
Its portfolio companies
where they are based, and what their own sites showSite status
- Site answers5100%
- No longer answers00%
- Points to another company00%
- Parked or sold domain00%
A site that stops answering three checks in a row is counted as no longer answering; that is not proof of closure. A site that points to another company is often an acquisition.
Investment themes
share of its checked companiesThis firmAll checked companies
Show as a table
| This firm | All checked companies | |
|---|---|---|
| Healthcare & Biotech | 100% | 15% |
Co-investor network
who it backs companies with, and who they back togetherCompare Panakes Partners head to head
portfolio size, rounds, entry stages, themes and the companies both backThree or more firms at once: portfolio overlap.
Funds
from public registers and its siteRecent portfolio activity
when companies last raised with Panakes Partners| Date | Company | Stage |
|---|---|---|
| 19 Oct 2026 | Series C+ | |
| 7 Apr 2026 | Series C+ | |
| 5 Oct 2025 | Series A | |
| 10 Sept 2024 | Series B Led | |
| 16 Jan 2024 | Seed |
Round details for Panakes Partners
Amounts, full round histories and every co-investor in Panakes Partners' rounds are on Fundup AI. VCinfo covers investors and their portfolios.
Portfolio
5 companies checked against their own sites| Company | What it does | Themes | First round with it | Evidence |
|---|---|---|---|---|
| Corflow develops solutions for detecting and treating microvascular disease, specifically microvascular obstruction in heart attack patients. | Healthcare & Biotech | Sept 2024Series B | Funding round | |
| Disco Pharmaceuticals develops targeted cancer therapies using its cell surfaceome discovery technology. | Healthcare & Biotech | Jan 2024Seed | Funding round | |
| Endovascular Engineering develops medical devices for removing blood clots | Healthcare & Biotech | Apr 2026Series C+ | Funding round | |
| A preclinical-stage biotechnology company developing inhaled nanoparticle-based drug delivery for cardiovascular conditions such as heart failure with reduced ejection fraction. | Healthcare & Biotech | Oct 2025Series A | Funding round | |
| Nouscom is a next-generation immunotherapy company developing engineered viral vectored vaccines for treatment of cancer. | Healthcare & Biotech | Oct 2026Series C+ | Funding round |
About this data
site last read 5 Nov 2026- Site
- panakes.it
- Last read
- 5 Nov 2026
- Watching since
- 5 Nov 2026
- Rounds since
- 16 Jan 2024
- Companies checked
- 5
Rates come from what VCinfo has observed since observation_start. Firms tend to remove companies that closed, so early rates understate reality. A company leaving a portfolio page does not mean it closed or exited. An unreachable site means our checks failed, nothing more.
Get Panakes Partners' profile as data
Pull Panakes Partners' portfolio, co-investors and changes through one API key or MCP, open every portfolio row, compare it with other firms, and get an email when it adds a company or files a fund.
Work email, sign-in link by email. Already have an account? Log in- Ask AI5 plain-English investor searches a day
- Full listsEvery portfolio row and two-firm overlap
- API and MCP100 REST or MCP calls a month, one key
- AlertsFollow 5 investors for portfolio and fund changes
$ curl -H "X-API-Key: YOUR_KEY" \
https://api.vcinfo.io/v1/firms/panakes.it
# also
GET /v1/firms/panakes.it/portfolio
GET /v1/firms/panakes.it/coinvestors
GET /v1/firms/panakes.it/news